Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.130
-0.090 (-2.80%)
At close: Jul 17, 2026, 4:00 PM EDT
3.235
+0.105 (3.34%)
After-hours: Jul 17, 2026, 7:59 PM EDT
Prime Medicine Market Cap
Prime Medicine has a market cap or net worth of $565.33 million as of July 17, 2026. Its market cap has increased by 6.80% in one year.
Market Cap
565.33M
Enterprise Value
544.35M
1-Year Change
6.80%
Ranking
Category
Stock Price
$3.13
ChartMarket Cap Chart
Since the IPO on October 20, 2022, Prime Medicine's market cap has decreased from $1.63B to $565.33M, a decrease of -65.26%. That is a compound annual growth rate of -24.61%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 17, 2026 | 565.33M | -7.97% |
| Dec 31, 2025 | 614.32M | 64.88% |
| Dec 31, 2024 | 372.58M | -54.41% |
| Dec 29, 2023 | 817.15M | -49.22% |
| Dec 30, 2022 | 1.61B | -1.12% |
| Oct 20, 2022 | 1.63B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Allogene Therapeutics | 617.83M |
| Achieve Life Sciences | 611.85M |
| AgomAb Therapeutics NV | 606.74M |
| Nuvectis Pharma | 586.37M |
| REGENXBIO | 579.03M |
| Tectonic Therapeutic | 578.34M |
| Relmada Therapeutics | 572.70M |
| 4D Molecular Therapeutics | 566.67M |